tracken
Editas Medicine, Inc. Aktie News
Neutral
GlobeNewsWire
●
ein Tag alt
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.
Neutral
Seeking Alpha
●
etwa ein Monat alt
Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Semenkow - Citigroup Inc., Research Division Alec Stranahan - BofA Securities, Research Division Mehdi Goudarzi - Truist Securities, In...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
●
etwa ein Monat alt
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
Neutral
GlobeNewsWire
●
etwa ein Monat alt
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: One-on-one MeetingsDate: Wednesday, September 3Locat...
Positiv
The Motley Fool
●
etwa 2 Monate alt
Gene-editing company Editas Medicine (EDIT -4.06%) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence, thanks to a well-received quarterly earnings report and business update.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026
Positiv
The Motley Fool
●
etwa 2 Monate alt
Editas Medicine (EDIT 2.50%), a small-cap biotech company, is up by 81% since January. But zooming out gives us a completely different picture.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
